New genes have been added to Sensorineural Hearing Loss and Hypothyroidism and Thyroid Hormone Resistance panels.
We have upgraded our hereditary ataxia testing menu. In addition to the comprehensive panel, repeat expansion analysis for SCA1, SCA2, SCA3 and SCA6 is also available.
Asper Pharmacogenetics testing menu has been updated with Contraceptives + HRT PGx test. Malignant hyperthermia panel now includes the STAC3 gene.
All NGS panels in our testing menu now include CNV analysis. Panels for frontotemporal dementia, tuberous sclerosis, microcephaly, and hereditary spastic paraplegia cover the analysis of clinically relevant non-coding variants.
Asper Biogene has launched a new pharmacogenetic test – Antidepressants PGx – for assessing metabolic response to antidepressant medications.
Microcephaly and hereditary spastic paraplegia panels have been updated with multiple new genes.
